As per reports, Britain has entered deals to buy 90 million doses of two possible COVID-19 vaccines from an alliance of Pfizer Inc (PFE) and BioNTech, and French group Valneva. Britain has signed in to procure 30 million doses of the early to mid-stage trials BioNTech/Pfizer vaccine and 60 million doses of the Valneva vaccine, which is still in pre-clinical trials. The deal is open for more than 40 million doses of the vaccine if proven to be successful.
Britain now has three different types of vaccines in-line and a total of 230 million doses potentially available. It also has an agreement with AstraZeneca for 100 million doses of its potential vaccine under development and in partnership with the University of Oxford. Britain has also secured treatments containing COVID-19-neutralising antibodies from AstraZeneca to save people who can’t be vaccinated. Financial terms of the deal were not disclosed.
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products. To learn more about Pfizer (PFE) and to track its progress please visit the Vista Partners Pfizer Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.